ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BÀNG QUANG TĂNG HOẠT BẰNG SOLIFENACIN 5 MG SAU 1 THÁNG TẠI BỆNH VIỆN TRƯỜNG ĐẠI HỌC Y DƯỢC CẦN THƠ

Abstract

  Background: Overactive bladder (OAB) is a syndrome characterized by involuntary detrusor contractions, leading to urinary urgency, increased urinary frequency, and nocturia. The prevalence of OAB tends to increase with age and is often underdiagnosed or inadequately treated. Currently, various treatment modalities for OAB have been implemented; however, therapeutic effectiveness varies among patient populations. Therefore, evaluating treatment outcomes in patients with OAB is necessary to improve diagnostic accuracy and therapeutic efficacy. Objectives: To describe the clinical and paraclinical characteristics and to evaluate treatment outcomes in patients with overactive bladder. Materials and methods: This was a prospective longitudinal pre–post treatment study including 33 patients diagnosed with overactive bladder who were treated with solifenacin 5 mg at Can Tho University of Medicine and Pharmacy Hospital from 12/2023 to 12/2025. Results: A total of 33 patients were enrolled, with a mean age of 54.6 ± 17.2 years. The mean Overactive Bladder Symptom Score (OAB-SS) was 7.2 ± 1.8, and the mean Quality of Life (QoL) score was 4.0 ± 0.8 at baseline. After one month of treatment, significant improvements were observed in both OAB-SS (from 7.2 to 3.6) and QoL scores (from 4.0 to 2.2). The most common adverse event was dry mouth (12.1%). No patients discontinued treatment due to adverse drug reactions. Conclusions: Pharmacological treatment of overactive bladder demonstrated significant improvement in clinical symptoms and patients’ quality of life. Solifenacin was generally well tolerated; however, careful monitoring and individualized treatment strategies are recommended to achieve optimal therapeutic outcomes.